医保局:国家组织药品集中采购和使用试点在全国推开
据《人民日报》报道,国家医疗保障局等9部门日前印发《关於国家组织药品集中采购和使用试点扩大区域范围的实施意见》,明确在全国范围内推广国家组织药品集中采购和使用试点集中带量采购模式,使全国符合条件的医疗机构能够提供质优价廉的试点药品,进一步降低群众用药负担。
此前,国家组织药品集中采购和使用试点(下称「4+7」试点)已经在11个城市推开,今年4月1日起全部落地实施。意见明确,试点扩围继续坚持「国家组织、联盟采购、平台操作」的总体思路,由国家统一组织,试点城市和先行跟进试点的省份之外25省(区)和新疆生产建设兵团形成联盟,开展跨区域联盟集中带量采购。由上海市医药集中招标采购事务管理所承担联合采购办公室日常工作并负责具体实施。
采购的药品仍为「4+7」试点中选的25个通用名药品,坚持高质量标准,通过(含视同通过)一致性评价的仿制药、参比制剂、原研药才有资格参与竞价。允许多家中选,每个药品中选企业一般不超过3家;中选价格低於「4+7」试点中选价格,采购的协议期限设定为1-3年。
意见明确,该轮联盟采购的政策措施是带量采购,以量换价。以当地医保定点医药机构药品用量年度药品总用量的50%至70%估算采购总量,进行带量采购,以量换价。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.